In this study, investigators wanted to determine the effect of T2DM susceptibility gene mutations on self-expression.
Participants (T2DM patients and controls) were recruited to identify genotypes and detect the levels of T2DM susceptibility genes expression in the fresh peripheral plasma. The normal pancreatic tissues or adjacent tissues of pancreatic cancer were also collected to identify the expression differences of T2DM susceptibility genes under different genotypes.
no drug therapy; 25 to 70 years old; Hemoglobin A1c (HbA1c) 7%-12%; BMI 20-35 kg/m2; Stable body weight (≤10% change within 3 months)（For newly diagnosed patients with T2DM）.
25 to 60 years old; BMI 19-26 kg/m2; in good health, with no abnormalities of motor system, digestive system, respiratory system, urogenital system, blood system, circulatory system, nervous/mental system, endocrine system, etc（For healthy subjects）.
20-80 years old; surgical resection of part or all of the pancreas; pancreatic lesions confirmed by enhanced CT or magnetic resonance (MR) examination or confirmed by intraoperative and postoperative pathology（For the patients in general surgical）.
had taken antidiabetic drugs;
had a history of pancreatic surgery;
Complicated with severe organ lesions;
Long-term use of drugs that affect pancreatic function.
Single group
Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs
DrugCompared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.
Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs
DrugThe newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection. In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing.
Detection of T2DM susceptibility gene expression in newly diagnosed T2DM patients
To detect the expression levels of susceptible genes in the plasma and the pancreatic tissues of newly diagnosed T2DM patients and compared with those in healthy subjects.
Detection of T2DM susceptibility gene expression in controls
To detect the expression levels of susceptible genes in the plasma and the pancreatic tissues of controls and compared with those in newly diagnosed T2DM patients.
Correlation between T2DM susceptibility gene expression and clinicopathological features
Incidence of clinical pancreatic diseases under expression differences in T2DM susceptibility genes
Baseline BMI of newly diagnosed with T2DM patients with different genotypes
Baseline BMI of newly diagnosed with T2DM patients
Baseline waist hip ratio (WHR) of newly diagnosed with T2DM patients with different genotypes
Baseline WHR of newly diagnosed with T2DM patients
Baseline fasting plasma glucose (FPG) of newly diagnosed with T2DM patients with different genotypes
Baseline FPG of newly diagnosed with T2DM patients
Baseline HbA1c of newly diagnosed with T2DM patients with different genotypes
Baseline HbA1c of newly diagnosed with T2DM patients
Click on the lead sponsor to view all of their trials.
